George Robinson/iStock via Getty Images
- Bausch + Lomb said that it has made progress in its development of tonabersat (BL1243), an oral treatment for dry age-related macular degeneration, following a meeting with the US FDA.
- The company noted that discussions with the agency yielded “greater clarity
